Literature DB >> 33803197

Soluble Fraction from Lysate of a High Concentration Multi-Strain Probiotic Formulation Inhibits TGF-β1-Induced Intestinal Fibrosis on CCD-18Co Cells.

Francesca Lombardi1, Francesca Rosaria Augello1, Paola Palumbo1, Elona Mollsi1, Maurizio Giuliani1,2, Anna Maria Cimini1,3, Maria Grazia Cifone1, Benedetta Cinque1.   

Abstract

Fibrosis is a severe complication of chronic inflammatory disorders, such as inflammatory bowel disease (IBD). Current strategies are not fully effective in treating fibrosis; therefore, innovative anti-fibrotic approaches are urgently needed. TGF-β1 plays a central role in the fibrotic process by inducing myofibroblast differentiation and excessive extracellular matrix (ECM) protein deposition. Here, we explored the potential anti-fibrotic impact of two high concentration multi-strain probiotic formulations on TGF-β1-activated human intestinal colonic myofibroblast CCD-18Co. Human colonic fibroblast CCD-18Co cells were cultured in the presence of TGF-β1 to develop a fibrotic phenotype. Cell viability and growth were measured using the Trypan Blue dye exclusion test. The collagen-I, α-SMA, and pSmad2/3 expression levels were evaluated by Western blot analysis. Fibrosis markers were also analyzed by immunofluorescence and microscopy. The levels of TGF-β1 in the culture medium were assessed by ELISA. The effects of commercially available probiotic products VSL#3® and Vivomixx® were evaluated as the soluble fraction of bacterial lysates. The results suggested that the soluble fraction of Vivomixx® formulation, but not VSL#3®, was able to antagonize the pro-fibrotic effects of TGF-β1 on CCD-18Co cells, being able to prevent all of the cellular and molecular parameters that are related to the fibrotic phenotype. The mechanism underlying the observed effect appeared to be associated with inhibition of the TGF-β1/Smad signaling pathway. To our knowledge, this study provides the first experimental evidence that Vivomixx® could be considered to be a promising candidate against intestinal fibrosis, being able to antagonize TGF-β1 pro-fibrotic effects. The differences that were observed in our fibrosis model between the two probiotics used could be attributable to the different number of strains in different proportions.

Entities:  

Keywords:  CCD-18Co cells; Smad 2/3; TGF-β1; VSL#3®; Vivomixx®; collagen-I; intestinal fibrosis; α-SMA

Year:  2021        PMID: 33803197      PMCID: PMC7998462          DOI: 10.3390/nu13030882

Source DB:  PubMed          Journal:  Nutrients        ISSN: 2072-6643            Impact factor:   5.717


  34 in total

Review 1.  Effect of probiotics on respiratory, gastrointestinal and nutritional outcomes in patients with cystic fibrosis: A systematic review.

Authors:  Jacqueline L Anderson; Caitlin Miles; Audrey C Tierney
Journal:  J Cyst Fibros       Date:  2016-09-29       Impact factor: 5.482

Review 2.  Effects of genetic, processing, or product formulation changes on efficacy and safety of probiotics.

Authors:  Mary Ellen Sanders; Todd R Klaenhammer; Arthur C Ouwehand; Bruno Pot; Eric Johansen; James T Heimbach; Maria L Marco; Julia Tennilä; R Paul Ross; Charles Franz; Nicolas Pagé; R David Pridmore; Greg Leyer; Seppo Salminen; Duane Charbonneau; Emma Call; Irene Lenoir-Wijnkoop
Journal:  Ann N Y Acad Sci       Date:  2014-02       Impact factor: 5.691

3.  NF-E2-Related Factor 2 Suppresses Intestinal Fibrosis by Inhibiting Reactive Oxygen Species-Dependent TGF-β1/SMADs Pathway.

Authors:  Yadi Guan; Yue Tan; Weiyu Liu; Jun Yang; Dongxu Wang; Di Pan; Yan Sun; Changqing Zheng
Journal:  Dig Dis Sci       Date:  2017-08-16       Impact factor: 3.199

Review 4.  ESPEN guideline: Clinical nutrition in inflammatory bowel disease.

Authors:  Alastair Forbes; Johanna Escher; Xavier Hébuterne; Stanisław Kłęk; Zeljko Krznaric; Stéphane Schneider; Raanan Shamir; Kalina Stardelova; Nicolette Wierdsma; Anthony E Wiskin; Stephan C Bischoff
Journal:  Clin Nutr       Date:  2016-12-31       Impact factor: 7.324

5.  A probiotic complex, rosavin, zinc, and prebiotics ameliorate intestinal inflammation in an acute colitis mouse model.

Authors:  Jin-Sil Park; JeongWon Choi; Ji Ye Kwon; Kyung-Ah Jung; Chul Woo Yang; Sung-Hwan Park; Mi-La Cho
Journal:  J Transl Med       Date:  2018-02-21       Impact factor: 5.531

6.  Divergent Effectiveness of Multispecies Probiotic Preparations on Intestinal Microbiota Structure Depends on Metabolic Properties.

Authors:  Michele Biagioli; Daniela Capobianco; Adriana Carino; Silvia Marchianò; Chiara Fiorucci; Patrizia Ricci; Eleonora Distrutti; Stefano Fiorucci
Journal:  Nutrients       Date:  2019-02-02       Impact factor: 5.717

Review 7.  The Epithelial-to-Mesenchymal Transition as a Possible Therapeutic Target in Fibrotic Disorders.

Authors:  Jacopo Di Gregorio; Iole Robuffo; Sonia Spalletta; Giulia Giambuzzi; Vincenzo De Iuliis; Elena Toniato; Stefano Martinotti; Pio Conti; Vincenzo Flati
Journal:  Front Cell Dev Biol       Date:  2020-12-21

8.  Production Conditions Affect the In Vitro Anti-Tumoral Effects of a High Concentration Multi-Strain Probiotic Preparation.

Authors:  Benedetta Cinque; Cristina La Torre; Francesca Lombardi; Paola Palumbo; Michel Van der Rest; Maria Grazia Cifone
Journal:  PLoS One       Date:  2016-09-22       Impact factor: 3.240

Review 9.  Targeting TGF-β Mediated SMAD Signaling for the Prevention of Fibrosis.

Authors:  Kelly L Walton; Katharine E Johnson; Craig A Harrison
Journal:  Front Pharmacol       Date:  2017-07-14       Impact factor: 5.810

Review 10.  Cellular and Molecular Mediators of Intestinal Fibrosis.

Authors:  Ian C Lawrance; Gerhard Rogler; Giorgos Bamias; Christine Breynaert; Jon Florholmen; Gianluca Pellino; Shimon Reif; Silvia Speca; Giovanni Latella
Journal:  J Crohns Colitis       Date:  2017-12-04       Impact factor: 9.071

View more
  1 in total

Review 1.  Therapeutic Targeting of Intestinal Fibrosis in Crohn's Disease.

Authors:  Giovanni Santacroce; Marco Vincenzo Lenti; Antonio Di Sabatino
Journal:  Cells       Date:  2022-01-26       Impact factor: 6.600

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.